MedTrace Logo

Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults

NCT00697242 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 362

Last updated 2008-06-13

No results posted yet for this study

Summary

In the present study the immunogenicity, reactogenicity and safety of recombinant hepatitis B vaccines with and without MPL will be evaluated in older healthy subjects

Conditions

Interventions

BIOLOGICAL

Engerix™-B

Intramuscular injection, 3 doses

BIOLOGICAL

Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL

Intramuscular injection, 3 doses

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1994-01-31
Primary Completion
1995-11-30
Completion
1995-11-30

Countries

  • Austria
  • Belgium
  • Denmark
  • Iceland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00697242 on ClinicalTrials.gov